Tag: Public health

  • Mega-Farms Are Driving the Threat of Bird Flu

    Mega-Farms Are Driving the Threat of Bird Flu

    [ad_1]

    In the West, where herds of thousands of cattle are common, researchers are seeing cases rise at poultry and dairy operations. More than 50 workers have contracted the virus.

    [ad_2]

    Source link

  • RFK Plans to Take on Big Pharma. It’s Easier Said Than Done

    RFK Plans to Take on Big Pharma. It’s Easier Said Than Done

    [ad_1]

    But the administration would likely face legal challenges if it proposed additional restrictions or an outright ban on pharma ads, says Jim Potter, executive director of the nonpartisan Coalition for Healthcare Communications. “The courts view advertising as a form of commercial speech, and they’ve ruled in a series of cases dating back to the 1970s that banning advertising violates First Amendment protections of freedom of speech,” he says. “If the administration wanted to unilaterally impose new rules, they would be on shakier legal ground today than in past years.”

    That’s because the US Supreme Court last summer overturned the longstanding Chevron doctrine, which allowed federal agencies some latitude in how they interpreted ambiguous laws. The Supreme Court ruling shifts power from agencies like the FDA to the courts.

    Ballreich and Weissman worry that Kennedy’s support of raw milk, vitamins, and disproven treatments for Covid-19, including ivermectin and hydroxychloroquine, could lead to the agency approving medicines that lack scientific evidence.

    “I think when Robert Kennedy talks about fighting corruption and Big Pharma monopolies, that is going to translate into reducing standards at FDA to enable the authorization and promotion of ineffective and dubious therapies, drugs, herbs, whatever,” Weissman says.

    As HHS secretary, Kennedy would not be directly responsible for approving new drugs or treatments. That job falls to the FDA’s Center for Drug Evaluation and Research, which more often than not approves drugs based on the recommendations of independent advisory committees. But in a handful of controversial cases, the agency has approved drugs against this expert advice, such as when it greenlit Exondys 51, a drug for Duchenne muscular dystrophy, in 2016. FDA advisers said there was not enough evidence to show that the drug had actual clinical benefits.

    RFK has also called for more scrutiny of vaccines, which already must be tested on thousands of healthy volunteers for several years before being licensed. This skepticism could play out in fewer vaccines making it to the market and more postmarket monitoring of approved vaccines.

    Working with Mehmet Oz, Trump’s pick to lead the Centers for Medicare and Medicaid Services, Kennedy could push to get questionable treatments or medical devices covered by Medicare, the federal health insurance program for people aged 65 or older and those with disabilities.

    But Kennedy’s anti-pharma stance could be tempered by congressional Republicans, who have been historically reticent about more regulation, and Trump’s other appointees. The incoming president has made a more conventional pick for FDA commissioner in Marty Makary, a pancreatic surgeon and public policy researcher at Johns Hopkins. Meanwhile, Vivek Ramaswamy, founder of the pharmaceutical company Roivant Sciences and a Republican presidential candidate, has been tapped to lead the Department of Government Efficiency, or DOGE, a planned presidential advisory commission under the second Trump administration.

    “There are huge question marks with the Trump administration and its approach to pharmaceuticals in general,” Ballreich says. “It’s hard to know how this is really going to shake out.”

    [ad_2]

    Source link

  • How the latest materials are taking biosensors to the next level

    How the latest materials are taking biosensors to the next level

    [ad_1]

    A CG illustration showing soft blue bottlebrush shapes interspersed with long grey mesh tubes

    A rendering of a bottlebrush elastomer and carbon-nanotube composite that researchers believe has potential use as a brain electrode.Credit: Xu, P. et al. Nature Commun. 14, 623 (2023)/CC BY 4.0

    When Shuai Xu set out to create a wearable biosensor to monitor the vital signs of premature infants and newborns, he faced a major challenge: the skin of these children is so delicate that the adhesive used to attach a sensor could damage it, potentially leading to infection. The stiff device pulling against the skin as the baby moved, and the wires that might pull it in a different direction, added to the problem. The solution was to build a sensor that was soft and stretchable, with flexible circuit boards and thin, 50-millimetre wires, a huge change from the rigid devices that had long been a mainstay of this type of engineering. It was encased in a bendable silicone, transmitted its readings via Bluetooth, and was stuck to the body using a hydrogel, a polymer-based substance made mostly of water. Xu, a dermatologist, helped develop the device as a postdoctoral researcher in the laboratory of John Rogers, an engineer and materials scientist at Northwestern University in Evanston, Illinois, a pioneer in soft materials.

    Xu went on to become a founder and chief executive of Sibel Health in Chicago, Illinois, a medical device company that won Nature’s Spinoff Prize in 2020 and sells wearable sensors for monitoring patients. Xu’s challenges are common among researchers trying to develop biosensors and the materials that go into creating them. The devices must be small and lightweight, and must attach to the body with minimum irritation. In some cases, they require long-lasting batteries and circuitry that can handle a growing suite of artificial-intelligence algorithms that make sense of the data they collect.

    According to one estimate, the global market for health sensors was worth an estimated US$42.6 billion in 2023 and expected to grow to US$142.2 billion by 2030. The wrist-worn or finger-worn devices that were designed to count steps can now measure heartbeat and blood-oxygen levels, and they’ve been joined by patches that allow diabetics to perform continuous monitoring of their glucose levels.

    “That’s nothing to sneeze at,” Xu says. “But there are so many other things that are out there, biochemical and biophysical, that we still can’t do in a practical, continuous way.” Figuring out how to measure a variety of physical and chemical signals cheaply and non-invasively could provide diagnostic information that could reshape medicine. And this might go beyond sensors that take mechanical measurements, such as heart rate. Researchers are also working on chemical sensors that can detect biomarkers in blood, sweat and tears, as well as in fluids that surround cells.

    Aida Ebrahimi, a biosensor engineer at Pennsylvania State University in State College, is working on materials that can detect neurotransmitters in saliva or urine such as dopamine, serotonin, adrenaline and noradrenaline, which change in people with diseases such as Parkinson’s or Alzheimer’s. She’s focused on 2D materials, which are only one atomic layer thick, such as molybdenum disulfide. With a material in which, effectively, the “whole thing is surface, you are going to get high sensitivity in the ability to detect a very low concentration of biomolecules”, says Ebrahimi. The material properties of such atomically thin films are also sensitive to surface modification. For example, attaching molecules of manganese gives the material an affinity for dopamine, creating an ultrasensitive detector1.

    The upper torso of a small baby in a NICU cot shown with caring hands in shot and traditional wire monitors; a plaster-like clear wireless biosensor is visible on its' chest

    A soft and stretchable sensor was developed for a newborn’s sensitive skin.Credit: Northwestern University

    Similar materials with different molecules attached could be used as sensors for other chemicals that can provide information about health, says Ebrahimi. Her team built a prototype of the sensor in 2020 that they showed could measure dopamine1, but building it and validating it for use could be several years off.

    One measuring challenge is that a lot of signalling, particularly in the brain, is performed by the movement of ions, whereas most monitoring equipment is designed to detect electrical currents carried by the flow of electrons. Sahika Inal, a bioengineer at KAUST in Thuwal, Saudi Arabia, is using organic electrochemical transistors (OECTs)2, devices that can detect signals from biomolecules, cells and lipid layers and turn them into readings that can be measured by electronic equipment. OECTs can be built using organic mixed ionic–electronic conductors (OMIECs), which have been the focus of much interest in the past few years. OMIECs are polymers that both ions and electrons can flow across easily. When part of the transistor experiences a small change in a property it is measuring, the OMIEC amplifies that signal. Because it’s an organic polymer, the material is much more compatible with the wet environment of the body than a standard electronic transistor, which has to be encapsulated to protect it from fluids. As a result, electronics can be developed “that can be integrated directly with the biological system,” Inal says.

    OECT’s could be printed directly on the skin’s surface to detect biological signals, for instance, or built on top of threads of fabric to create biosensing garments and wraps that could survive washing. They also have the potential to replace the stiff electrodes used in brain implants to control prosthetic devices and monitor electrical activity in seizure patients. Their flexibility and biocompatibility might cause less irritation to brain tissue, which can render the electrodes less sensitive.

    At the University of Toronto, mechanical engineer, Xinyu Liu, and chemical engineer, Helen Tran, have developed another material with the softness and flexibility to be used as a brain electrode3. Dubbed the bottlebrush elastomer, their rubber-like substance is made from a molecule that has a long, stiff spine, which maintains its structure, surrounded by short, flexible bristles, for softness. To give the material electrical conductivity, Liu and Tran add a filler — either carbon nanotubes or a mixture of silver flakes and eutectic gallium indium, a semiconductor in liquid form. They worry, though, that the filler could leech out and have toxic effects, so they’d like to eliminate it. “Ultimately, we would like to design a polymer that is soft and electron-conducting,” Tran says. “These demands are often at odds.”

    Liu’s lab is also working on wearable sensors. One, based on a hydrogel, is designed to conform to the skin and measure strain when a body part, a knee, for example — is bent4. Such a device could be useful in monitoring an athlete’s performance or assessing arthritis.

    Another sensor they are developing places nanowires of zinc oxide on a cotton thread to create electronic textiles that can measure substances such as lactate and sodium in sweat. The material could be woven into a shirt or a sweatband to monitor an athlete’s health5.

    Xu sees a lot of opportunities for new biosensors. “AI is generating new algorithms,” he says, that can then be integrated into sensors to learn from, and react, to measurements they’re recording. That would require developing processors that can work with the limited power available in a sensor. Better batteries might help, as would alternatives such as harvesting power from movement or body heat, he says. Devices that can combine readings — glucose levels with heart rate, for instance — could be transformative, he says. He would also like to be able to detect stress hormones that could be used to monitor fatigue, or drug metabolites to check patients have taken medications.

    Biosensors have the potential to collect a lot of useful information, and to do it in everyday settings that might give a more realistic picture of health than a one-time doctor’s test. “Whether you’re ill or not”, says Xu, people do not spend most of their time in a clinic or hospital. The ability to track health “and use the technology yourself, I think is really important”.

    [ad_2]

    Source link

  • Meet the Latina scientists advancing health and policy

    Meet the Latina scientists advancing health and policy

    [ad_1]

    Life as a scientist in Latin America isn’t always easy — and this is especially true for women. Latina researchers have had to find creative ways to bypass the gender gap from an early age: at 15, girls are half as likely as boys to expect that they’ll work in a science, technology, engineering and mathematics (STEM) area. According to the United Nations, in 2016, less than half (45%) of Latin America’s workforce in research and development were women. Although this figure is above the world average (38%), it is low compared with graduation rates for women in Latin American countries.

    Nature spoke to four Latin American researchers about the peaks and troughs they have faced in their careers and how they are connecting science and policy.

    ILIANA CURIEL: A translator between cultures

    Paediatrician and researcher at the Colombian Institute of Family Welfare in La Guajira, Colombia.

    A portrait of Iliana Curiel

    Iliana Curiel became a paediatrician to help her local community in La Guajira, Colombia.Credit: Iliana Curiel Arismendy

    I am a mix of Black and Wayuu. I grew up in Uribia, a municipality located in La Guajira, Colombia, at the northernmost tip of South America.

    Health challenges in La Guajira are different from those in the rest of Colombia. Although non-transmittable diseases such as obesity and heart conditions demand a considerable effort from public-health services in large cities, the greatest issue in La Guajira is child malnutrition. A child in the region is 60 times more likely to die from undernourishment than is a child living in Bogotá. Most of La Guajira is a desert and access to water can be limited. In some parts of the region, water services reach less than 10% of the population. Around 40% of the population in the territory is under 19, so there is an immense need for paediatric care there. Like other rural and Indigenous communities in Colombia and South America, this is a place where the ‘multidimensional poverty index’ is high and preventable infant and mother mortality abounds.

    Growing up in La Guajira, I decided to be a paediatrician and help my community. But I also wanted more than that: after my medical degree in the mid-1990s, I went on to study public health and social policy.

    Indigenous communities in La Guajira do not easily accept Western medicine because their cultural practices differ from those in urban settings — and public-health policies rarely meet on common ground with these cultural singularities. So, in 2018, I went back there and, together with my wife, started a non-governmental organization, Los Hijos del Sol (Children of the Sun). Our goal has been to conduct research by listening to Indigenous communities, allowing us to plan more adequate models of health care.

    Once, for example, we needed to care for a severely undernourished boy. But to offer proper care, we needed to take him from the community to a hospital — and to do that, we had to ask for permission from the community leaders. Because we were in a matrilineal-led group — in which the line of descent is considered from the mothers’ side — it was the boy’s maternal uncles, not his parents, who spoke for the child. So we had to contact his uncle first. A health team, unaware of this, might have asked the boy’s mother for authorization and had a hard time gaining it. If the family think a certain disease is rooted in a spell or bad spirits, we can’t say it’s nonsense — we must adapt our approach and find a shared understanding.

    At Los Hijos del Sol, we train Indigenous mothers and midwives to take steps to reduce child mortality. We ask mothers how they know when their child is in trouble, and they come up with the most beautiful analogies. They won’t say the child is “breathing quickly”, but that the child is in a “high tide”, as if the chest and abdomen were moving like restless waves — and they know that it is a sign of alarm.

    Most physicians avoid politics, but public health is a political matter and we must be aware of that if we ever want to change things for the better. I’d tell young Latina researchers to never lose sight of your purpose. The path in science, to women, is one of perseverance and resistance, but also of transformation. The qualities that are said to disqualify us as scientists — such as empathy and creativity — are the ones we should take most pride in.

    Iliana Curiel providing care to a newborn baby

    Child malnutrition in La Guajira is one of the biggest issues in the region, says Iliana Curiel (left).Credit: Organización Los Hijos del Sol

    XÓCHITL CASTAÑEDA: A voice to Latin American immigrants

    Programme director and professor in the School of Public Health at the University of California, Berkeley.

    Around 30 years ago, I moved from Mexico City to the United States for my postdoctoral research and it was here that I first saw the negative health impacts felt by immigrants. In the early 2000s, a large number of the migrant community came from Mexico and Latin America. Although the number of migrants from other countries has grown, Mexicans are still the main immigrant workforce in the United States — we’re about 10.6 million people.

    During my research at the University of California in San Francisco, I visited the fields where farm workers were employed, and it completely changed my life. I saw the terrible conditions in which they were living to perform the most dangerous, belittling and dirty jobs.

    I am a medical anthropologist; in the mid-1990s, I was conducting research on the risks that immigrants faced regarding HIV and AIDS. After witnessing neglect and abuse of migrant workers, I realized I couldn’t just stay in academia — I needed to translate research into public action. And this was the beginning of the Health Initiative of the Americas, a programme on health and migration at the University of California, Berkeley.

    Since its inception in 2001, the programme has relied on around 20,000 volunteers working to grow a grass-roots movement. I was very fortunate to be part of the University of California system: it helped me to knock at the door of the Mexican government. Because of the magnitude of the Mexican diaspora in the United States, the Mexican government has 50 consulates in the United States. The Mexican government partnered with the programme, and this has opened the doors to cooperation with other Latin American countries, such as Guatemala, El Salvador and Honduras. In the United States, health is unfortunately not a human right — it is sometimes seen as a commodity. We want to extend access to health care to immigrants, who are excluded from the health system, to help improve their living conditions.

    We wanted to hold National Health Weeks, just like the ones in Mexico — when the government mobilizes health personnel across the country to knock at houses to give everyone a chance to get vaccinated three times a year. But without accredited health providers, that wouldn’t be possible in the United States. So, we sought out community clinics, and many other organizations started to join: our network has several partners nationwide, including health and cultural institutions and consulates. These are places where immigrants, regardless of their legal status, can access basic health services and advice. Even in remote regions of the United States, they can get vaccines and education about preventive health to improve their overall quality of life.

    Young Latina researchers have the opportunity and the responsibility to contribute to a more equitable world. My advice is to never give up. Even in hard times there is light, and public health is a marvellous instrument to shine that light.

    DENISE LAPA: A fetoscopy pioneer

    Fetal and neonatal surgery programme coordinator at Sabará Child Hospital in São Paulo, Brazil.

    In 1999, I started to develop a technique to treat spina bifida — a pre-birth condition in which the neural tube bulges on the back of the fetus. The condition can damage nerves in the spinal cord and greatly affect a child’s ability to walk or perform day-to-day activities.

    In the late 1990s, Thomas Kohl, who is now head of the German Center for Fetal Surgery and Minimally-Invasive Therapy at the University Medical Center Mannheim, developed a technique to close the gap that forms in the spine. His idea was to stitch the fetus’s spine without opening the mother’s womb. I had been testing a similar technique for a decade when, in 2012, he invited me to Germany. We started an informal exchange.

    The difference between Kohl’s technique and mine was that, instead of stitching all of the layers in the back of a fetus — spinal cord, muscle and skin tissues — my team and I used a biocellulose patch over the spinal tissue to help it self-heal and avoid suturing the fetus’s spinal cord to the tissue above it.

    Throughout my career, I felt I had to prove myself all the time as a woman and, as a Latina researcher, I also had regional prejudice on top of that. To me, it seemed that some people, most of whom were men, felt that if a breakthrough in fetoscopy (fetal endoscopy) was to be made, it wouldn’t be made by a woman and certainly not one from Brazil.

    However, in 2013, after 14 years of testing in animal models, our first fetal surgery at the Samaritan Hospital of São Paulo proved that the technique worked. A decade later, we could see that not only was it viable, but also that it yielded positive long-term results. A study1 following 78 children who had undergone our procedure showed that almost half of them (46%) could walk independently once they reached between 2.5 and 10 years old — and almost all of them (94%) had expected social function. In comparison, a 2020 study2 on the effectiveness of the conventional open-womb surgical technique showed that around 29% of children aged 6 and over who had undergone this surgery could walk independently. Previous studies have shown that the effectiveness of the conventional technique in terms of walking rates is as high as 45%3.

    As well as in Brazil, our technique is now used in Israel, Chile, Uruguay, Italy and parts of the United States. It’s also rising in popularity: more than 300 surgeries have been performed outside Brazil. Everything I did in my life, I accomplished because a man told me I couldn’t. It’s extremely rewarding to see children, whose parents relied on my team, being able not only to walk, but also to jump and play freely — some even go skiing and do ballet.

    My piece of advice to young Latina researchers would be: structural sexism is still not understood by most men. It is up to us, women, to occupy important spaces and teach our daughters a different language of love and respect between men and women.

    YESTER BASMADJIÁN:On the front line against insect-borne diseases

    Head of the Department of Parasitology and Mycology in the Medicine Faculty at the University of the Republic in Montevideo, Uruguay.

    Yester Basmadjián sitting at her desk

    Yester Basmadjián says protecting against misinformation is an important part of her job.Credit: Ramiro Tomasina

    Before the viral disease dengue returned to Uruguay in 2016, the last epidemic had been a century earlier, in 1916. In the late 1950s, the country had eradicated the mosquito vector Aedes aegypti through monitoring populations and their behaviour. But, because the continent never fully got rid of it, the mosquito returned in 1997. Despite heavy public campaigning, the country was unable to eradicate it again. Now we’re seeing a rise in local transmission of dengue, especially in the Montevideo region and Salto on the border with Argentina. There were 48 confirmed cases in 2023, and this year we have seen more than 700.

    Cases of dengue, most of which were imported by travellers from neighbouring countries such as Brazil, Argentina and Paraguay, are now a concern in Montevideo. At the University of the Republic in Montevideo, we have a laboratory in which we can study this and other disease-vector insects more closely. Our lab has the support of Uruguay’s Public Health Ministry, the International Atomic Energy Agency (IAEA) and the Pan American Health Organization, and we have partnered with a number of institutions in Brazil and other Latin American countries.

    We’re using X-rays (hence our partnership with the IAEA) to sterilize male A. aegypti mosquitoes before they become adults, to decrease their overall population. Female mosquitoes mate only once; if they mate with sterile males then they won’t produce offspring. Another advantage is that male mosquitoes generally don’t interact with people and, because they do not feed on blood, they don’t transmit diseases. Our project will not eliminate this insect in Uruguay, but it’s a tool that will add to the fight. It is certainly better than open-air insecticide spraying — we don’t know whether mosquitoes in Uruguay are resistant to certain chemicals. We’re launching close to 30,000 first-generation sterile mosquitoes at the end of this year and are looking forward to good results.

    One of our biggest challenges is ensuring that the new lab remains operational in both the medium and long term — not only by maintaining resources, but also by protecting against a wave of misinformation and conspiracy theories. Many people think that sterilization of mosquitoes is going to cause a change in human bodies (which is not possible even if a male mosquito interacted with a person). At the lab, we try to counter this through outreach with journalists and by promoting workshops in schools.

    Although sterilizing mosquitoes is not a silver bullet to end dengue, it’s an important tool, and the public’s cooperation is essential to fight the mosquito that transmits it.

    My advice to young Latina researchers is that we have to study a lot to adapt to an ever more technological world — but it’s important never to give up when faced with challenges. Always move forward and, at some point, you’ll get to where you want to be.

    [ad_2]

    Source link

  • Wuhan lab samples hold no close relatives to virus behind COVID

    Wuhan lab samples hold no close relatives to virus behind COVID

    [ad_1]

    Shi Zhengli wearing protective clothing in a biosafety lab.

    Chinese virologist Shi Zhengli has presented evidence that her lab has not worked with close relatives of SARS-CoV-2.Credit: Johannes Eisele/AFP via Getty

    After years of rumours that the virus that causes COVID-19 escaped from a laboratory in China, the virologist at the centre of the claims has presented data on dozens of new coronaviruses collected from bats in southern China. At a conference in Japan this week, Shi Zhengli, a specialist on bat coronaviruses, reported that none of those viruses stored in her freezers are the most recent ancestors of the virus SARS-CoV-2.

    Shi was leading coronavirus research at the Wuhan Institute of Virology (WIV), a high-level biosafety laboratory, when the first cases of COVID-19 were reported in that city. Soon afterwards, theories emerged that the virus had leaked — either by accident or deliberately — from the WIV.

    Shi has consistently said that SARS-CoV-2 was never seen or studied in her lab. But some commentators have continued to ask whether one of the many bat coronaviruses her team collected in southern China over decades was closely related to it. Shi promised to sequence the genomes of the coronaviruses and release the data.

    The latest analysis, which has not been peer reviewed, includes data from the whole genomes of 56 new betacoronaviruses, the broad group to which SARS-CoV-2 belongs, as well as some partial sequences. All the viruses were collected between 2004 and 2021.

    “We didn’t find any new sequences which are more closely related to SARS-CoV-1 and SARS-CoV-2,” said Shi, in a pre-recorded presentation at the conference, Preparing for the Next Pandemic: Evolution, Pathogenesis and Virology of Coronaviruses, in Awaji, Japan, on 4 December. Earlier this year, Shi moved from the WIV to the Guangzhou Laboratory, a newly established national research institute for infectious diseases.

    The results support her assertion that the WIV lab did not have any bat-derived sequences from viruses that were more closely related to SARS-CoV-2 than were any already described in scientific papers, says Jonathan Pekar, an evolutionary biologist at the University of Edinburgh, UK. “This just validates what she was saying: that she did not have anything extremely closely related, as we’ve seen in the years since,” he says.

    The closest known viruses to SARS-CoV-2 were found in bats in Laos and Yunnan, southern China — but years, if not decades, have passed since they shared their closesta common ancestor with the virus that causes COVID-19. “She’s basically found a lot of what we expect,” says Leo Poon, a virologist at the University of Hong Kong.

    Longtime collaboration

    For decades, Shi collaborated with Peter Daszak, president of the EcoHealth Alliance, a New York City-based non-profit organization, to survey bats in southern China for coronaviruses and study their risk to humans. The work was funded by the US National Institutes of Health and the US Agency for International Development, but in May this year, the government suspended federal funding to EcoHealth because it had not provided adequate oversight of research activities at the WIV. Those activities included modifying a coronavirus linked to severe acute respiratory syndrome (SARS), to study the potential origins of this type of virus in bats.

    [ad_2]

    Source link

  • How safe is the US food supply?

    How safe is the US food supply?

    [ad_1]

    Produce has been the source of many foodborne illness outbreaks in the US this year

    The Image Party/Shutterstock

    Apple sauce containing lead. Onions carrying E. coli. Deli meat spreading listeria. The past year has seen alert after alert from US public health officials warning of contamination in the food supply, both in packaged and prepared foods. Going to the grocery store – or even out to eat – has seemingly become a real gamble.

    But lately, much of the public worry over food safety has been hijacked by Robert…

    [ad_2]

    Source link

  • Common chemical in drinking water hasn’t been tested for safety

    Common chemical in drinking water hasn’t been tested for safety

    [ad_1]

    New Scientist. Science news and long reads from expert journalists, covering developments in science, technology, health and the environment on the website and the magazine.

    Millions of US residents may be drinking water containing the potentially harmful compound

    Yiu Yu Hoi/Getty Images

    A common disinfectant in drinking water breaks down into a chemical compound that we know almost nothing about, including whether it has any potential toxic health effects to those who drink it.

    Chlorine has been used to sanitise drinking water for more than a century. However, some drinking water systems in the US, UK and Australia now use another closely related chemical disinfectant called chloramine. That’s because chlorine byproducts were linked to bladder and colon cancer, low birth rates and miscarriage, says …

    [ad_2]

    Source link

  • Donald Trump to Nominate Anti-Vaccine Activist Robert F. Kennedy Jr. to Oversee US Public Health

    Donald Trump to Nominate Anti-Vaccine Activist Robert F. Kennedy Jr. to Oversee US Public Health

    [ad_1]

    President-elect Donald Trump announced that he would nominate former independent presidential candidate Robert F. Kennedy Jr. to run the Department of Health and Human Services (HHS). It’s the fulfillment of an implied promise that Trump made at a rally at Madison Square Garden in New York in late October, where he said he would let Kennedy “go wild on health.”

    Kennedy, a former Democrat and scion of the wealthy political family, first rose to prominence as an environmental lawyer and anti-vaccine activist. Around 2015, he joined the board of the nonprofit Children’s Health Defense (CHD), which alleges that conditions like autism and attention deficit hyperactivity disorder (ADHD) are caused by environmental factors, including harmful agents in vaccines. Kennedy has repeatedly spread misinformation about vaccines, and in 2021 was named by the Center for Countering Digital Hate as one of the “disinformation dozen,” spreading misinformation about the Covid-19 pandemic across Instagram, Twitter, and Facebook.

    He has suggested, in contradiction to all reputable scientific research, that Covid-19 may have been “ethnically targeted” to spare Ashkenazi Jews and Chinese people and that HIV does not cause AIDS, and implied that vaccine mandates are worse than the Holocaust. He also said in a 2012 deposition that a worm ate part of his brain and then died.

    Kennedy’s account was banned from Instagram in 2021 for spreading vaccine misinformation. His account was restored in 2023, when he announced his run for office.

    In August, Kennedy suspended his campaign and threw his support behind Trump, saying, “If President Trump is elected and honors his word, the vast burden of chronic disease that burdens and bankrupts the country will disappear,” at the time. He launched a parallel slogan to Trump’s MAGA—Make America Healthy Again (MAHA)—focused on “prioritizing regenerative agriculture, preserving natural habitats, and eliminating toxins from our food, water, and air.”

    HHS oversees 13 federal agencies—which Kennedy has indicated he would gut—including the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control (CDC).

    Kennedy’s position, however, is still contingent on congressional approval. Previous HHS leaders have had long careers in the public health field or within the department itself before serving as the head. A Republican-controlled Senate might defer to Trump, or might point to Kennedy’s aggressive promotion of conspiracy theories, long career as a loyal Democrat, and muddled positions on abortion as reasons to block his accession.

    Though Kennedy has promised to overhaul the entire system, experts who spoke to WIRED say that he would likely come up against longstanding regulations that would be hard to outmaneuver. Health policies are also heavily informed by advisory committees, which are stacked with medical and public health experts, and would take time to shift in order to fully change the government’s recommendations.

    Still, Kennedy as HHS director would have substantial power to dismiss staff and declare public health emergencies.

    [ad_2]

    Source link

  • Resistance to crucial malaria drug detected in severely ill kids in Africa

    Resistance to crucial malaria drug detected in severely ill kids in Africa

    [ad_1]

    A young girl suffering from malaria sits in a hospital bed in Amuria, Uganda.

    A child in Amuria, Uganda, is treated for malaria.Credit: Jake Lyell/Alamy

    Scientists have detected resistance to artemisinin, a key malaria drug, for the first time among children in Africa with severe disease. The continent accounts for 95% of all deaths from malaria globally, and children are the most badly affected.

    “If this is verified by other studies, it could change guidelines for treatment of severe malaria in African children, and they are the biggest target group by far,” says Chandy John, a specialist in paediatric infectious diseases at Indiana University in Indianapolis. John is a co-author of the study, published in JAMA1 and presented today at the Annual Meeting of the American Society of Tropical Medicine and Hygiene, in New Orleans, Louisiana.

    Artemisinin resistance has been detected in children in Africa previously, but the fact that it has now been identified specifically in children with severe malaria raises the threat level. The parasite that causes malaria, Plasmodium falciparum, is contracted through the bite of a mosquito. For treating ‘uncomplicated’, or non-severe, cases of malaria, the World Health Organization recommends a course of pills containing an artemisinin derivative, which rapidly eliminates most malaria parasites in the body, combined with a ‘partner’ drug that circulates in the body for longer and kills the remaining parasites. These regimens are called artemisinin-based combination therapies (ACTs).

    For severe malaria, which can involve symptoms such as convulsions, breathing problems and abnormal bleeding, treatment is more intensive. Physicians administer intravenous artesunate — a fast-acting version of artemisinin — for at least 24 hours. This is followed by a course of ACT. Treating severe malaria rapidly is crucial for recovery, researchers say.

    Tough to treat

    The latest study, in Jinja, Uganda, looked at children aged 6 months to 12 years with severe malaria. The researchers found that 11 of the 100 participants, or about 10%, showed partial artemisinin resistance. This term refers to a delay in the clearance of the malaria parasite from the body after treatment; a partially resistant infection is classified as one in which the drug takes longer than 5 hours to kill half of the malaria parasites.

    In the past, researchers have connected specific mutations in P. falciparum proteins with the emergence of partial artemisinin resistance2 — meaning that the parasites are evolving to evade the ‘gold standard’ malaria treatment. John and colleagues analysed the genomes of the parasites infecting children in their study, and found that ten participants had one of two types of these mutations. One of the mutations, detected in eight participants, was associated with artemisinin taking longer than usual to clear the parasite.

    Another group of ten children in the study had a malaria infection that recurred after their treatment concluded. These cases were not attributable to the presence of any known artemisinin-resistance mutations. Instead, John thinks the recurrence might have been caused by resistance to lumefantrine, a partner drug administered orally in the ACT step of the treatment regimen for severe malaria. But more studies are needed to evaluate that possibility, John says. “What the recurrence suggests to us is that maybe that partner drug is not working as well as it should, because the parasites are coming back,” he adds.

    Since resistance to artemisinin was first identified in southeast Asia in the 2000s, scientists’ biggest concern has been how it will affect the treatment of severe cases of malaria, says Philip Rosenthal, a malaria specialist at the University of California, San Francisco. “Even if the drug still works, that slower action could make a difference and lead to higher levels of mortality,” he says.

    But the study by John and his colleagues doesn’t provide a definitive answer to whether artemisinin resistance is already leading to worse clinical outcomes, Rosenthal notes. The study size was too small, and all the children analysed eventually recovered, even if this process sometimes took longer than expected. That just shows that current treatments for severe malaria aren’t “quite as good as we might have hoped”, he says.

    Rosenthal and others are still worried about this news, however. “The emergence of artemisinin partial resistance in Africa is a major threat to malaria control,” he says. “We are now only starting to understand what’s going on.”

    [ad_2]

    Source link

  • A Popular Decongestant Doesn’t Work. The FDA Is Finally Doing Something About It

    A Popular Decongestant Doesn’t Work. The FDA Is Finally Doing Something About It

    [ad_1]

    In a long-sought move, the US Food and Drug Administration on Thursday formally began the process of abandoning oral doses of a common over-the-counter decongestant that the agency concluded last year is not effective at relieving stuffy noses.

    Specifically, the FDA issued a proposed order to remove oral phenylephrine from the list of drugs that drugmakers can include in over-the-counter products—also known as the OTC monograph. Once removed, drugmakers will no longer be able to include phenylephrine in products for the temporary relief of nasal congestion.

    “It is the FDA’s role to ensure that drugs are safe and effective,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a statement. “Based on our review of available data and consistent with the advice of the advisory committee, we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal decongestant.”

    For now, the order is just a proposal. The FDA will open up a public comment period, and if no comments can sway the FDA’s previous conclusion that the drug is useless, the agency will make the order final. Drugmakers will get a grace period to reformulate their products.

    Reviewed Reviews

    The slow-moving abandonment of phenylephrine is years in the making. The decongestant was originally approved by the FDA in 1976, but it came to prominence after the “Combat Methamphetamine Epidemic Act of 2005” came into effect, and pseudoephedrine—the main component of Sudafed—moved behind the pharmacy counter to keep it from being used to make methamphetamine. With pseudoephedrine out of easy reach at drugstores, phenylephrine became the leading over-the-counter decongestant. And researchers had questions.

    In 2007, an FDA panel reevaluated the drug, which supposedly works by shrinking blood vessels in the nasal passage, opening up the airway. While the panel upheld the drug’s approval, it concluded that more studies were needed for a full assessment. After that, three large, carefully designed studies were conducted—two by Merck for the treatment of seasonal allergies and one by Johnson & Johnson for the treatment of the common cold. All three found no significant difference between phenylephrine and a placebo.

    Last year, the FDA reevaluated the drug again, taking into consideration the new studies and taking a deeper look at the 14 studies from the 1950s to 1970s that earned phenylephrine its initial approval. The FDA noted that those 14 studies assessed congestion using a dubious measure of nasal airway resistance that has since been abandoned. But even with the shoddy measurement, the studies provided mixed efficacy results. And the overall finding of efficacy hinged on only two of the studies, which were conducted at the same lab.

    Too Good to Be Real

    No other lab was ever able to replicate the positive results from those two studies. And when FDA scientists carefully looked through the data, they found evidence that some of the numbers could have been fudged and that the results were “too good to be real.”

    As a final nail in phenylephrine’s coffin, modern studies suggest that when phenylephrine is taken orally, it’s highly metabolized in the gut, leaving less than 1 percent of the consumed dose as active in the body. The finding explains why oral doses don’t cause the constriction of blood vessels throughout the body that could lead to an uptick in blood pressure—a side effect sometimes seen with pseudoephedrine. While researchers initially thought the lack of blood pressure increases was a positive finding, in retrospect, it was a hint that the drug wasn’t working.

    With that, a panel of advisers for the FDA voted unanimously, 16 to 0, that oral doses of phenylephrine are not effective at treating a stuffy nose. Afterward, CVS announced that it would remove products that had phenylephrine as the sole active ingredient.

    Despite the seemingly damning evidence, the industry group representing makers of phenylephrine-containing products—the Consumer Healthcare Products Association (CHPA)—still disputed the FDA’s move.

    “CHPA is disappointed in FDA’s proposal to reverse its long-established view of oral PE [phenylephrine],” CHPA CEO Scott Melville said in a statement Thursday. The CHPA maintains its position on the drug’s efficacy. “As science and methods advance, new data should be considered in the context of the full weight of available evidence, not as a complete replacement of the previous body of evidence—especially when considering an ingredient as safely and widely used as PE. CHPA will review the Proposed Order and submit comments accordingly,” Melville said.

    This story originally appeared on Ars Technica.

    [ad_2]

    Source link